PT-141 (Bremelanotide)
Bremelanotide, Vyleesi, PT-141, the "arousal peptide"
The Ground Truth Score
four plain questions, never one numberFDA-approved for women; off-label everything else is thinner
Bottom line
A genuine FDA-approved drug for one narrow indication (low desire in premenopausal women), but the popular gray-market use, on-demand libido in men, rests on small observational data and anecdote, and the cardiovascular and pigmentation signals are real.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
Can you legally get it?
FDA-approvedPrescription medicineAn approved drug with a label, a manufacturer, and a prescribing route. This is the only tier where what is in the vial is guaranteed by anyone. Check the indication, though: approval is always for something specific, and it is rarely the use this compound is popular for.
Bremelanotide is FDA-approved (Vyleesi, June 21 2019) for acquired generalized hypoactive sexual desire disorder in PREMENOPAUSAL WOMEN. That indication is the whole approval. The popular use in men and in postmenopausal women is off-label and rests on much thinner evidence, and an earlier intranasal program was halted by FDA in 2007 over blood-pressure increases.
Legal status as of 2026-06-16. This is a separate axis from the grades above, and it does not move them. A vote about who may legally prepare a compound is not evidence that the compound works.
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓Approved (Vyleesi): 1.75 mg subcutaneously (abdomen or thigh) at least 45 minutes before anticipated sexual activity; no more than one dose per 24 hours and no more than 8 doses per month.
Reported, not prescribed. Verify your vial and your math.
First documented human use
Human trials date to the early 2000s, when Palatin Technologies tested an intranasal formulation in both male erectile dysfunction and female sexual dysfunction. Those Phase 2 programs were halted by the FDA in 2007 over blood-pressure increases. The reformulated subcutaneous drug (Vyleesi) was FDA-approved on 21 June 2019 for acquired, generalized HSDD in premenopausal women, making it one of the very few peptides on this site backed by completed, registered human RCTs.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. We grade each one below.
- FDA-approved (as Vyleesi) for acquired, generalized hypoactive sexual desire disorder in premenopausal women.
- Acts centrally on melanocortin receptors in the brain to raise sexual desire/arousal, rather than acting on blood flow like PDE5 inhibitors (Viagra/Cialis).
- Taken on-demand before anticipated activity, not daily.
- Used off-label in men and postmenopausal women for low libido, though it is not approved for either.
The data behind each bullet
What actually backs it
Bremelanotide is FDA-approved (Vyleesi, June 2019) for acquired, generalized HSDD in premenopausal women - the first melanocortin agonist approved for a sexual-desire indication (afamelanotide, an MC1R agonist, was FDA-approved earlier, in 2019, for erythropoietic protoporphyria).
FDA approval supported by two identical Phase 3 randomized, double-blind, placebo-controlled trials (RECONNECT, ~1,247 women).
DailyMed. VYLEESI (bremelanotide) label ↗Two Phase 3 RCTs showed statistically significant improvements in the desire and distress endpoints (FSFI-desire and FSDS-DAO item 13) versus placebo, with a 52-week open-label extension showing no new safety signals.
Published Phase 3 trials and long-term open-label extension in peer-reviewed literature.
PubMed. Bremelanotide HSDD Phase 3 trials ↗Effect size in the trials was statistically significant but modest, and the placebo response was substantial, a recurring critique of HSDD endpoints, which are subjective self-report scales.
Reported trial deltas on subjective questionnaire endpoints; large placebo arm response is documented in the Phase 3 data.
PubMed, bremelanotide RECONNECT efficacy ↗Use in men is off-label and rests on much weaker evidence, early intranasal ED trials (halted in 2007) plus small recent observational case series, not RCTs.
Original male ED program discontinued over blood-pressure concerns; subsequent male data is limited observational/case-series (e.g., ~21-patient series).
PubMed, bremelanotide men erectile dysfunction ↗The intranasal formulation was abandoned because the FDA halted Phase 2 trials in 2007 over clinically meaningful blood-pressure increases.
Documented regulatory history of the Palatin intranasal program.
ClinicalTrials.gov, bremelanotide trials ↗Prove it
Can you tell if it's working?
The honest test: if it's working, is there any objective way to see it — a blood marker, a scan, a wearable? For a lot of peptides the answer is no, and that's worth knowing before you spend on labs or gear.
No objective non-blood tracker exists — PT-141's only efficacy endpoint is subjective sexual desire/arousal, so you verify it by how you feel, not by any scan, wearable, or lab.
Bloodwork
Nothing on a routine panel confirms this one. Anyone who says otherwise is guessing.
PT-141 (bremelanotide) is a centrally-acting melanocortin receptor agonist (primarily MC4R on hypothalamic neurons). Its therapeutic effect is a subjective, CNS-mediated increase in sexual desire/arousal. It does not act on an endocrine or metabolic axis that releases a measurable circulating analyte, so nothing about its efficacy appears in routine bloodwork.
Read this before you spend on labs
Routine bloodwork cannot confirm PT-141 is working. Its action is neurobehavioral: it drives sexual desire/arousal via central melanocortin (MC4R) signaling, and the only human-validated endpoints are subjective self-reported desire and distress scales (the FDA RECONNECT phase 3 trials). There is no orderable lab that reflects this efficacy. The one objective, measurable effect on the FDA label is a transient rise in blood pressure (with a small reflex drop in heart rate) after dosing, but that is a vital-sign safety/pharmacodynamic signal, not bloodwork, and it indicates only drug exposure, not therapeutic benefit. Efficacy here can only be judged by the user's own experience, which makes this compound high placebo-risk.
- FDA Prescribing Information — VYLEESI (bremelanotide), NDA 210557 (2019): MC-receptor agonist; HSDD indication; efficacy by subjective desire/distress scales; transient BP elevation as the objective pharmacodynamic/safety signal ↗
- Kingsberg SA et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT). Obstet Gynecol. 2019 — efficacy measured only by self-reported desire and distress, no biomarker endpoint ↗
Bottom line
PT-141 (bremelanotide) works centrally at MC3R/MC4R to raise sexual desire, and its efficacy in humans is measured only by self-reported scales (FSFI desire domain, FSDS-DAO distress, desire diaries) — there is no validated objective proxy for libido. No non-blood modality applies: urine, stool, CGM, VO2max, DEXA, body composition, and genetics are all irrelevant to its mechanism, and sleep/HRV wearables track nothing it acts on. The one objective physical sign — a transient ~6 mmHg systolic BP rise (with a small heart-rate drop) on a cuff — reflects drug exposure and MC4R activity, NOT whether desire improved, so it is a safety/pharmacodynamic signal and is deliberately excluded as an efficacy channel. Placebo risk is high (dosing right before planned intimacy under peak expectancy), which is exactly why an objective readout would help and exactly why none exists. Honest verdict: track this with a simple pre/post desire-and-distress diary, not with any device or panel.
Logging baseline vs retest is the whole game. The Truth Tracker is our free log for bloodwork, DEXA, genetics, and wearable data — bring your own numbers.
How to track it →Mechanism
How it's assumed to work
Assumed · theoretical pathway
Bremelanotide is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist (MC1R, MC3R, MC4R, MC5R; not MC2R), acting primarily via MC3R/MC4R. The proposed central mechanism: activation of MC4R on neurons in the hypothalamus (medial preoptic area) modulates downstream dopamine signaling in brain reward/motivation circuits, increasing sexual desire and arousal. This is a CNS desire pathway, distinct from the vascular/erectile mechanism of PDE5 inhibitors. Because it is an approved drug, the mechanism is reasonably established rather than purely assumed, though the precise neurocircuitry linking MC4R to desire is still incompletely mapped. Off-target MC1R activation drives the pigmentation and tanning effects.
Dosing & handling
What users and clinicians report
Approved (Vyleesi): 1.75 mg subcutaneously (abdomen or thigh) at least 45 minutes before anticipated sexual activity; no more than one dose per 24 hours and no more than 8 doses per month. Off-label/gray-market protocols often cite a similar ~1–2 mg subcutaneous range, sometimes lower to manage nausea. Reported, not prescribed.
The approved product is a fixed-dose single-use autoinjector; reconstituting a research vial introduces dose-measurement error the regulated product does not have. The 8-doses-per-month ceiling exists specifically to limit cumulative blood-pressure exposure and hyperpigmentation, it is a safety limit, not an efficacy one. Nausea is dose-related, which is why some users titrate below 1.75 mg.
Timing & food
Taken on-demand at least ~45 minutes before anticipated sexual activity, reflecting the time to peak central effect and the short half-life. Food/fasted status is not a labeled requirement, but because nausea is the headline side effect, some users deliberately dose on a lighter stomach or pair it with an anti-nausea strategy; the drug can also slow gastric emptying, which is why it can reduce absorption of co-administered oral medications.
Half-life
Elimination half-life approximately 2.7 hours (range ~1.9–4.0 hours); plasma levels decline biphasically after peak. Short half-life is consistent with its on-demand, pre-activity dosing.
Reconstitution sensitivity
The regulated product (Vyleesi) ships as a pre-filled single-use autoinjector requiring no reconstitution, eliminating handling error. Gray-market lyophilized PT-141 must be reconstituted with bacteriostatic water, kept refrigerated once mixed, protected from light and repeated freeze-thaw, and used within a limited window; peptide degradation from poor handling reduces potency unpredictably. Reconstitution sensitivity is therefore a gray-market-only concern, but a real one.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
High discussion volume across men's-health and TRT forums (ExcelMale and similar) and a large vendor/affiliate footprint, since it is one of the most marketed gray-market peptides. Volume is inflated by commercial sources, which should be discounted.
Consistency
Genuinely mixed. Responders describe a noticeable rise in arousal/desire and spontaneous erections within hours; a substantial minority report no libido effect at all, or get the side effects (cold/achy feeling, low mood for several hours, nausea) without the benefit. The split between strong responders and non-responders is one of the most consistent themes, which argues for high inter-individual variability.
Source credibility
Moderate. The for-women indication is anchored by real RCTs and an FDA label, which is far stronger than the typical peptide on this site. But the dominant off-label narrative (men, on-demand) is carried by anecdote plus small observational series, and much of the online enthusiasm originates from vendors who sell it, so credibility on the popular use case is capped.
- Anecdote, not proof: many users describe a real, noticeable jump in arousal and 'wanting to' within an hour or so of dosing, often framed as desire/headspace rather than just a mechanical erection.
- A recurring counter-theme is non-response: a meaningful share report the side effects (flushing, nausea, feeling cold/achy or low for several hours) with little or no change in libido, strong responders and non-responders both show up consistently.
- Nausea is the most-cited downside; some users titrate the dose down or report it fades with repeated use, while others find it bad enough to stop.
- Community sentiment commonly treats it as occasional/on-demand rather than a daily peptide, and experienced users flag the blood-pressure and skin-darkening warnings and caution against frequent dosing.
Placebo risk, High
The efficacy endpoints are subjective self-reported desire and distress scales, the experience is taken minutes before intentional intimacy (peak expectancy), and even the Phase 3 trials showed a large placebo-arm response. A subjective sexual outcome under high expectancy is close to a worst case for placebo susceptibility, hence High, despite the drug having a real pharmacological effect.
Risk panel
What could go wrong
Adverse events
Nausea is the dominant adverse effect, about 40% of treated women in Phase 3 trials, sometimes with vomiting (roughly 1 in 8), and severe enough that a meaningful share of trial participants needed anti-nausea medication or discontinued. Flushing (~20%), injection-site reactions (~13%), and headache (~11%) are also common.
Theoretical concerns
Melanocortin activation (MC1R) drives melanin production, so the same pathway that may cause incidental tanning also causes focal hyperpigmentation of the face, gums, and breasts, higher risk with darker skin and with frequent dosing, and resolution was not confirmed in all patients. The MC4R mechanism also produces transient blood-pressure elevation and heart-rate reduction with every dose.
Contraindications
Contraindicated in uncontrolled hypertension or known cardiovascular disease, and not recommended for those at high CV risk. Each dose causes a transient BP rise (label: max ~6 mmHg systolic / 3 mmHg diastolic) and HR drop, usually resolving within 12 hours. Do not exceed one dose per 24 hours or 8 doses per month, more frequent dosing increases both the hyperpigmentation risk and the cumulative time spent with elevated blood pressure. May slow gastric emptying and reduce absorption of oral drugs (e.g., a documented interaction reducing naltrexone exposure).
Honest unknowns
Long-term safety beyond ~1 year is not characterized. Off-label use in men and postmenopausal women lacks RCT safety data, and gray-market PT-141 (research-chemical vials, not the regulated Vyleesi autoinjector) carries unknown purity, dose accuracy, and sterility, none of the label's safety dataset applies to an unregulated vial. Cumulative cardiovascular risk from repeated on-demand dosing in people the label would have excluded is untested.
Confound watch
Off-label users frequently stack PT-141 with PDE5 inhibitors (sildenafil/tadalafil), testosterone/TRT, or other libido agents, any of which can independently change arousal or erectile function and muddy attribution. Expectancy is a major confounder for a subjective sexual outcome taken right before planned intimacy. An erection within hours of dosing (commonly reported) is not the same endpoint as increased desire, and the two are often conflated in anecdotes.
History
Discovery → first use → status
- Early 2000sPalatin Technologies tests intranasal bremelanotide (a derivative of melanotan II) in Phase 2 trials for male erectile dysfunction and female sexual dysfunction.
- 2007FDA halts the intranasal Phase 2 program over increased blood pressure in subjects; the intranasal route is abandoned in 2008.
- Late 2014Phase 3 trials of reformulated subcutaneous bremelanotide for HSDD begin (RECONNECT).
- 2017Palatin licenses U.S. development/commercialization rights to AMAG Pharmaceuticals; Phase 3 RECONNECT trials complete.
- 21 June 2019FDA approves Vyleesi (bremelanotide) for acquired, generalized HSDD in premenopausal women.
Verification
The COA standard, applied
Profile cross-checked against the FDA-approved VYLEESI label (DailyMed), the Wikipedia development-history summary (intranasal halt 2007, June 2019 approval, 2.7 h half-life, MC3/MC4 mechanism), and PubMed records of the Phase 3 RECONNECT trials and long-term extension. Adverse-event percentages and the daily-dosing hyperpigmentation figure (38% over 8 days) are taken directly from the label.
The full verification standard →Sources
Where this comes from
- DailyMed. VYLEESI (bremelanotide injection) label ↗· Authoritative FDA label: indication, dosing, contraindications, BP/HR and hyperpigmentation warnings, adverse-event rates.
- PubMed. Bremelanotide HSDD Phase 3 trials ↗· The two RECONNECT Phase 3 RCTs supporting approval.
- PubMed. Long-term safety/efficacy of bremelanotide ↗· 52-week open-label extension; no new safety signals.
- PubMed, bremelanotide erectile dysfunction / men ↗· Early intranasal ED program and small later observational male data (off-label).
- ClinicalTrials.gov, bremelanotide studies ↗· Registered trial record incl. the Phase 3 HSDD study (NCT02333071).
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.